Hovione Expands Formulation Capabilities

Hovione is investing in specialized formulation capabilities, beginning with the acquisition of a formulation facility adjacent to the current process chemistry and particle engineering facility in Loures, Portugal, the company announced on Oct. 19, 2015. This acquisition is a strategic investment to further boost development and manufacturing capabilities for both inhalation and oral dosage forms.

The facility will be engineered for highly potent APIs and moisture-sensitive compounds and will have dedicated rooms to allow for concurrent manufacture of these products. The facility will be capable of preparing a wide range of materials suitable for clinical trials and commercial batches meeting global regulatory requirements.